

EUREPA

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for **Eurepa** [Repaglinide 0.25mg, 0.5mg, 1mg and 2mg Tablets]
[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Eurepa lowers blood glucose levels by stimulating the release of insulin from the pancreas. Eurepa closes ATP-dependent potassium channels in the beta cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the beta-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion.

INDICATION: Indicated as an adjunct to diet and exercise to lower the blood glucose in patients with type-2 diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled satisfactorily by diet and exercise alone and also indicated for use in combination with Metformin to lower blood glucose in patients whose hyperglycemia cannot be controlled by exercise, diet, and either eurepa or metformin alone.

DOSAGE AND ADMINISTRATION: Short-term administration of eurepa may be sufficient during periods of transient loss of control in patients usually well controlled on diet. eurepa doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. For patients not previously treated or whose HbA1C is <8%, the starting dose should be 0.5 mg. For patients previously treated with blood glucose-lowering drugs and whose HbA1C is 8%, the initial dose is 1 or 2 mg with each meal preprandially.

CONTRAINDICATION: Contraindicated in patients with diabetic ketoacidosis, with or without coma, Type 1 diabetes, known hypersensitivity to the drug or its inactive ingredients, severe hepatic function disorder and concomitant use of gemfibrozil.

WARNINGS & PRECAUTIONS: Use cautiously in patient with hepatic insufficiency, elderly patients, hypoglycemia and in patients with HbA1c less than 8%. When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of glycemic control may occur. At such times, it may be necessary to discontinue eurepa and administer insulin.

DRUG INTERACTIONS: Gemfibrozil, ketoconazole, miconazole, erythromycin, troglitazone, rifampicin, barbiturates, carbamazepine, digoxin, theophylline, warfarin, NSAIDs, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid.

ADVERSE REACTIONS: Hypoglycemia, upper respiratory tract infections, nausea, vomiting, arthralgia, back pain, headache and ischemia.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/ EUREPA 0.25,0.5,1,2mg/AUG-2015/01/ABPI

(Additional information is available on request)